Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, School as Usual
Behavioral · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
5 Years to 14 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
OPC-64005, Atomoxetine, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
Conditions
ADHD
Interventions
ADHD Collaborative
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 11 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness Awareness Practices for ADHD (adapted), Services-As-Usual
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
17 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tuscaloosa, Alabama • Spartanburg, South Carolina
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

NCT01542528
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
IBBS
Behavioral
Lead sponsor
Yale University
Other
Eligibility
5 Years to 10 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Hamden, Connecticut • New Haven, Connecticut
Conditions
Tourette Syndrome, ADHD
Interventions
Modified Comprehensive Behavioral Intervention for Tics, Comprehensive Behavioral Intervention for Tics
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
AR11, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
Recruiting Not applicable Interventional

ADHD PreSMA Response Inhibition Therapy

NCT06325813
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Active repetitive TMS, Sham repetitive TMS
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

NCT05802680
Conditions
Attention Deficit Hyperactivity Disorder, Attention Difficulties, Attention Deficit, Cognitive Deficit, Wellness
Interventions
Transcranial photobiomodulation, Sham transcranial photobiomodulation
Device
Lead sponsor
Francisco Gonzalez-Lima, PhD
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Austin, Texas
Not listed Phase 2 Interventional Accepts healthy volunteers

Acute Effects of Stimulant Medication in College Students With ADHD

NCT03935646
Conditions
Attention Deficit Hyperactivity Disorder, Stimulant Use, Working Memory, Change in Sustained Attention, Mood
Interventions
Adderall IR 10mg, Placebo
Drug
Lead sponsor
University of Wyoming
Other
Eligibility
18 Years to 29 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Laramie, Wyoming
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions
Centanafadine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Conditions
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Disorder With Hyperactivity
Interventions
Quotient®, Usual Clinic ADHD Care
Device · Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
6 Years to 12 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Folsom, California • Roseville, California • Walnut Creek, California
Conditions
Pediatric Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exercise Intensity on ADHD Symptoms

NCT06753253
Conditions
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Cycling Exercise
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years to 26 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Kent, Ohio
Completed Not applicable Interventional

STAND Community Trial

NCT02694939
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
STAND (Behavior Therapy + Motivational Interviewing), Usual Care
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
11 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 28 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethlehem, Pennsylvania • Kingston, Rhode Island